High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

By Tedeschi Alessandra   Montillo Marco   Strocchi Elena   Cafro Anna   Tresoldi Elisabetta   Intropido Liliana   Nichelatti Michele   Marbello Laura   Baratè Claudia   Camaggi Carlo   Morra Enrica  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 771-779

Springer Publishing Company

Access to resources Recommend Favorite

Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells

By                  

Oncology Letters, Vol. 2, Iss. 3, 2011-01 ,pp. : 549-556

Spandidos Publications

Access to resources Recommend Favorite

Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reports

By                

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1321-1324

Spandidos Publications

Access to resources Recommend Favorite

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

By Klisovic Rebecca B.   Blum William   Liu Zhongfa   Xie Zhiliang   Kefauver Cheryl   Huynh Lenguyen   Zwiebel James A.   Devine Steven M.   Byrd John C.   Grever Michael R.   Chan Kenneth K.   Marcucci Guido  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1332-1336

Informa Healthcare

Access to resources Recommend Favorite

Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia

By              

Oncology Letters, Vol. 8, Iss. 2, 2014-01 ,pp. : 731-735

Spandidos Publications

Access to resources Recommend Favorite